CD155 is a putative therapeutic target in medulloblastoma.
Sean LiRoger McLendonEric SankeyReb KornahrensAnne-Marie LyneFlorence Marie Géraldine CavalliZachary McKayJames Emmett HerndonMarc RemkeDaniel PicardMatthias GromeierMichael BrownEric Michael ThompsonPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)
CD155 is expressed across medulloblastoma subgroups and subtypes. Blocking CD155 results in cell death and decreased cellular invasion. This study provides rationale for CD155-targeting agents including PVSRIPO and antibody-mediated blockade of CD155.